Repurposing edaravone in oncology: Bridging antioxidant defense and immune modulation

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Edaravone is a synthetic free radical scavenger approved for neurological disorders like stroke and amyotrophic lateral sclerosis (ALS).
• Emerging research suggests edaravone possesses anti-inflammatory and immunomodulatory properties relevant to cancer.
• These properties include inhibition of key signaling pathways (NF-κB, JAK2/STAT3, TLR4/IL-6) crucial in the tumor microenvironment.

Purpose of the Study:

• To review the potential of repurposing edaravone as an adjuvant cancer therapy.
• To explore the mechanistic basis for edaravone's anti-cancer effects.
• To evaluate its role in combination therapies and potential protective effects.

Main Methods:

• This review synthesizes existing literature on edaravone's mechanisms of action in cancer.
• It examines preclinical data on its effects on oncogenic signaling, cell cycle, apoptosis, and cancer stem cells.
• The review also considers its potential in combination with chemotherapy and radiotherapy.

Main Results:

• Edaravone disrupts oncogenic signaling pathways and induces cell cycle arrest and apoptosis, particularly in therapy-resistant cancer models.
• It demonstrates immunomodulatory effects by inhibiting key inflammatory pathways within the tumor microenvironment.
• Edaravone may enhance the efficacy of chemotherapy and radiotherapy while protecting normal tissues from toxicity.

Conclusions:

• Edaravone exhibits multifaceted anti-cancer activities, including antioxidant, anti-inflammatory, and immunomodulatory effects.
• Its ability to target cancer stem cells and overcome therapy resistance supports its potential as an adjuvant cancer therapy.
• While clinical data are limited, preliminary findings are encouraging, necessitating further research and clinical trials for edaravone in oncology.